NanoCarrier Overview

  • Year Founded
  • 1996

Year Founded

  • Status
  • Public

  • Employees
  • 17

Employees

  • Stock Symbol
  • 4571

Stock Symbol

  • Investments
  • 4

  • Share Price
  • $1.23
  • (As of Monday Closing)

NanoCarrier General Information

Description

Nano Mrna Co Ltd formerly NanoCarrier Co Ltd is engaged in the research and development of pharmaceuticals using micellar nanoparticles technology.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
TKS
Corporate Office
  • Ohnoya-Kyobashi Building
  • 1-4-10 Kyobashi
  • Tokyo, 104-0031
  • Japan
+81 00-0000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

NanoCarrier Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$1.23 $1.17 $1.09 - $2.09 $86.5M 70.4M 385K -$0.11

NanoCarrier Financials Summary

In Thousands,
USD
TTM 31-Dec-2023 FY 2023 31-Mar-2023 FY 2022 31-Mar-2022 FY 2021 31-Mar-2021
EV 70,881 100,265 103,567 129,003
Revenue 1,170 1,493 2,350 2,954
EBITDA (9,852) (16,812) (26,823)
Net Income (7,467) (9,684) (16,749) (26,743)
Total Assets 36,652 43,411 58,471 70,896
Total Debt 7,863 8,322 9,423 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

NanoCarrier Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore NanoCarrier‘s full profile, request access.

Request a free trial

NanoCarrier Patents

NanoCarrier Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20190008980-A1 Polyion complex capable of efficiently delivering mrna into living body, and drug and method for treating arthropathy in which said complex is used Inactive 31-Jul-2015 00000000000
EP-3329925-A1 Polyion complex capable of efficiently delivering mrna into living body, and drug and method for treating arthropathy in which said complex is used Active 31-Jul-2015 000000000
EP-3329925-B1 Polyion complex capable of delivering mrna into living body for treating arthropathy Active 31-Jul-2015 000000000
JP-6812346-B2 Polyion complex that can efficiently deliver mrna into the living body, and therapeutic agents and treatment methods for arthropathy using this Active 31-Jul-2015 000000000
EP-3329925-A4 Polyion complex capable of efficiently delivering mrna into living body, and drug and method for treating arthropathy in which said complex is used Active 31-Jul-2015 A61K47/6455 0
To view NanoCarrier’s complete patent history, request access »

NanoCarrier Executive Team (6)

Name Title Board Seat Contact Info
Tetsuhito Matsuyama Ph.D President & Chief Executive Officer
Hiroyuki Hanada Chief Operating Officer & Board Member
Shiro Akinaga President, Chief Strategy Officer & Managing Director of Research and Development Division
You’re viewing 3 of 6 executive team members. Get the full list »

NanoCarrier Board Members (2)

Name Representing Role Since
Hiroyuki Hanada NanoCarrier Chief Operating Officer & Board Member 000 0000
You’re viewing 1 of 2 board members. Get the full list »

NanoCarrier Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

NanoCarrier Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore NanoCarrier‘s full profile, request access.

Request a free trial

NanoCarrier Investments & Acquisitions (4)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
PrimRNA 01-Apr-2021 00000 0000 Drug Discovery 000000000
AccuRna 30-Sep-2020 0000000000 000.00 Drug Delivery
AccuRna 17-Jan-2018 00000 0000 00.000 Drug Delivery
AccuRna 16-Mar-2016 Seed Round 00.00 Drug Delivery
To view NanoCarrier’s complete investments and acquisitions history, request access »

NanoCarrier Subsidiaries (1)

Company Name Industry Location Founded
AccuRna Drug Delivery Bunkyo-ku, Japan 0000
To view NanoCarrier’s complete subsidiaries history, request access »

NanoCarrier ESG

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

Rank

Percentile

Pharmaceuticals

Industry

Rank

Percentile

Biotechnology

Subindustry

Rank

Percentile

To view NanoCarrier’s complete esg history, request access »

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »